12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Epi proColon 2 regulatory update

Epigenomics submitted the third module of a PMA to FDA for its Epi proColon 2.0 test to detect colorectal cancer. The company said the module included the analytical performance of the test in terms of accuracy, precision and stability. The company...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >